These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18259863)

  • 21. Medical treatment of gastroesophageal reflux disease.
    Bor S; Kalkan İH
    Turk J Gastroenterol; 2017 Dec; 28(Suppl 1):S48-S52. PubMed ID: 29199168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. It is difficult to discontinue PPI treatment in patients with GERD.
    Bjornsson E
    Am J Gastroenterol; 2011 Feb; 106(2):367-8; author reply 368. PubMed ID: 21301460
    [No Abstract]   [Full Text] [Related]  

  • 23. Esophagitis in children: an update on current pharmacotherapy.
    Shashidhar H; Tolia V
    Expert Opin Pharmacother; 2013 Dec; 14(18):2475-87. PubMed ID: 24138403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proton pump inhibitors: balancing the benefits and potential fracture risks.
    Richards JB; Goltzman D
    CMAJ; 2008 Aug; 179(4):306-7. PubMed ID: 18695170
    [No Abstract]   [Full Text] [Related]  

  • 25. [Gastroesophageal reflux disease: pathogenetic basis of differentiated tactics of treatment].
    Tkachenko EI; Uspenskiĭ IuP; Karateev AE; Bakulin IG; Pakhomova IG
    Eksp Klin Gastroenterol; 2009; (2):104-14. PubMed ID: 19552028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gastric histology in children treated with proton pump inhibitors long term, with emphasis on enterochromaffin cell-like hyperplasia.
    Hassall E; Owen D; Kerr W; Sturby T; Richardson P; El-Serag H
    Aliment Pharmacol Ther; 2011 Apr; 33(7):829-36. PubMed ID: 21320136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety profile of six months lansoprozole treatment in children.
    Eren M; Yıldırım SH; Sivrikoz IA
    Indian J Gastroenterol; 2010 Nov; 29(6):247-8. PubMed ID: 21221882
    [No Abstract]   [Full Text] [Related]  

  • 28. Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review.
    Cohen S; Bueno de Mesquita M; Mimouni FB
    Br J Clin Pharmacol; 2015 Aug; 80(2):200-8. PubMed ID: 25752807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proton Pump Inhibitors: The Good, Bad, and Ugly.
    Schnoll-Sussman F; Niec R; Katz PO
    Gastrointest Endosc Clin N Am; 2020 Apr; 30(2):239-251. PubMed ID: 32146944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. When proton pump inhibitors are compared, are there specific cases in which a certain proton pump inhibitors should be particularly preferred?
    Çelebi A; Yılmaz H
    Turk J Gastroenterol; 2017 Dec; 28(Suppl 1):S68-S70. PubMed ID: 29199172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PURLs: The benefits--and limits--of PPIs with warfarin regimens.
    Ludden-Schlatter A; Stevermer JJ
    J Fam Pract; 2017 Nov; 66(11):694-696. PubMed ID: 29099511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proton Pump Inhibitors: What the Internist Needs to Know.
    Spechler SJ
    Med Clin North Am; 2019 Jan; 103(1):1-14. PubMed ID: 30466666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation and Treatment of Patients with Persistent Reflux Symptoms Despite Proton Pump Inhibitor Treatment.
    Spechler SJ
    Gastroenterol Clin North Am; 2020 Sep; 49(3):437-450. PubMed ID: 32718563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Esophageal acid exposure on proton pump inhibitors in unselected asymptomatic gastroesophageal reflux disease patients.
    Grigolon A; Cantù P; Savojardo D; Conte D; Penagini R
    J Clin Gastroenterol; 2008 Oct; 42(9):969-73. PubMed ID: 18719508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-dinner administration increases the efficacy of proton pump inhibitors on refractory GERD symptoms in connective tissue disease patients.
    Iwata A; Ikeda K; Hirose K; Takatori H; Takahashi K; Sanayama Y; Tanaka S; Suto A; Nakajima H
    Mod Rheumatol; 2013 Mar; 23(2):357-64. PubMed ID: 22614239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system.
    Vasiliadis KV; Viazis N; Vlachogiannakos J; Sgouros SN; Stefanidis G; Archimandritis A; Karamanolis DG
    Am J Gastroenterol; 2010 Feb; 105(2):308-13. PubMed ID: 19809412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age.
    Sandström M; Davidson G; Tolia V; Sullivan JE; Långström G; Lundborg P; Brown K
    Clin Ther; 2012 Aug; 34(8):1828-38. PubMed ID: 22832034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ANTISECRETORY TREATMENT FOR PEDIATRIC GASTROESOPHAGEAL REFLUX DISEASE - A SYSTEMATIC REVIEW.
    Mattos ÂZ; Marchese GM; Fonseca BB; Kupski C; Machado MB
    Arq Gastroenterol; 2017 Dec; 54(4):271-280. PubMed ID: 28954042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs?
    Bruley des Varannes S; Coron E; Galmiche JP
    Best Pract Res Clin Gastroenterol; 2010 Dec; 24(6):905-21. PubMed ID: 21126703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential options to optimize therapy of gastroesophageal reflux disease with proton pump inhibitors.
    Tonini M; Vigneri S; Neri M; Cuomo R; Savarino V; Pace F
    Digestion; 2007; 76(3-4):171-8. PubMed ID: 18046084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.